Patents by Inventor Daryl Faulds

Daryl Faulds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION
    Publication number: 20150374715
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Application
    Filed: February 27, 2015
    Publication date: December 31, 2015
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
    Patent number: 8980944
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Gemmus Pharma Inc.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION
    Publication number: 20120190739
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Application
    Filed: March 28, 2011
    Publication date: July 26, 2012
    Applicant: GEMMUS PHARMA INC.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
    Patent number: 8183286
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: May 22, 2012
    Assignee: Gemmus Pharma Inc.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
    Patent number: 7563924
    Abstract: The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: July 21, 2009
    Assignee: Schering Aktiengesellschaft
    Inventors: Bernd Buchmann, Daryl Faulds, William Guilford, Gernot Langer, Judy Li, Bernhard Lindenthal, Werner Skuballa, Luisella Toschi
  • EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
    Publication number: 20090170931
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Application
    Filed: November 14, 2007
    Publication date: July 2, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • Novel fibroblast growth factors
    Publication number: 20080057076
    Abstract: Novel nucleic acids, polypeptide sequences, and nucleic acid regulators thereof, have been identified which code for a fibroblast growth factor (FGF), preferably FGF-20 or FGF-23, a class of polypeptides involved in development, differentiation, and morphogenesis, e.g., in cell-cell signalling and cell proliferation. An FGF of the present invention, fragments thereof, and derivatives thereof, have one or more of the following biological activities, e.g., promoting wound healing; promoting neuronal survival; stimulating cell proliferation, e.g., proliferation of stem cells, fibroblasts, neurons, glia, oligodendrocytes, Schwann cells, or progenitors thereof; modulating differentiation of cells; inducing embryonic development; stimulating neurite outgrowth; enhancing recovery from nerve or neuronal damage; stimulating myelination; stimulating angiogenesis; receptor binding activity; modulating tumorigenesis, etc.
    Type: Application
    Filed: June 22, 2007
    Publication date: March 6, 2008
    Applicant: Schering Aktiengesellschaft
    Inventors: Peter Bringmann, Daryl Faulds, Branislava Mitrovic, Subha Srinivasan
  • 5-Cyano-prostacyclin derivatives as agents for the treatment of autoimmune disease
    Publication number: 20080021099
    Abstract: The present invention is directed to the use of 5-cyano-prostacyclin derivatives as therapeutics for the treatment of autoimmune diseases.
    Type: Application
    Filed: July 16, 2007
    Publication date: January 24, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Daryl Faulds, William Guilford, Judy Li
  • 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
    Publication number: 20070203096
    Abstract: The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.
    Type: Application
    Filed: November 20, 2006
    Publication date: August 30, 2007
    Applicant: Schering Aktiengesellschaft
    Inventors: Bernd Buchmann, Daryl Faulds, William Guilford, Gernot Langer, Judy Li, Bernhard Lindenthal, Werner Skuballa, Luisella Toschi
  • Modulation of MDL-1 activity for treatment of inflammatory disease
    Publication number: 20070179094
    Abstract: The present invention provides compositions and methods that modulate MDL-1 activity in a cell, in vivo or in vitro. In particular, the present invention provides methods for treatment of inflammatory diseases using synthetic or recombinant compositions that modulate MDL-1 activity in a mammalian cell, in vivo or in vitro. More particularly, the present invention provides protein compositions useful for the treatment of diseases having an inflammatory process mediated by MDL-1.
    Type: Application
    Filed: January 26, 2007
    Publication date: August 2, 2007
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Daryl Faulds, Stefano Fiorucci, Ying-Ping Jiang, Yi Liu, John Parkinson
  • Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
    Publication number: 20030008376
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Application
    Filed: June 11, 2002
    Publication date: January 9, 2003
    Applicant: Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
    Publication number: 20030008391
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Application
    Filed: June 11, 2002
    Publication date: January 9, 2003
    Applicant: Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
    Publication number: 20030008279
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Application
    Filed: June 11, 2002
    Publication date: January 9, 2003
    Applicant: Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
    Publication number: 20030003447
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Application
    Filed: June 11, 2002
    Publication date: January 2, 2003
    Applicant: Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
    Patent number: 6475718
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: November 5, 2002
    Assignees: Schering Aktiengesellschaft, The Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Novel fibroblast growth factors
    Publication number: 20020151496
    Abstract: Novel nucleic acids, polypeptide sequences, and nucleic acid regulators thereof, have been identified which code for a fibroblast growth factor (FGF), preferably FGF-20 or FGF-23, a class of polypeptides involved in development, differentiation, and morphogenesis, e.g., in cell-cell signalling and cell proliferation. An FGF of the present invention, fragments thereof, and derivatives thereof, have one or more of the following biological activities, e.g., promoting wound healing; promoting neuronal survival; stimulating cell proliferation, e.g., proliferation of stem cells, fibroblasts, neurons, glia, oligodendrocytes, Schwann cells, or progenitors thereof; modulating differentiation of cells; inducing embryonic development; stimulating neurite outgrowth; enhancing recovery from nerve or neuronal damage; stimulating myelination; stimulating angiogenesis; receptor binding activity; modulating tumorigenesis, etc.
    Type: Application
    Filed: December 7, 2001
    Publication date: October 17, 2002
    Inventors: Peter W. Bringmann, Daryl Faulds, Branislava Mitrovic, Subha Srinivasan
  • METHODS AND COMPOSITIONS FOR MODULATING THE INTERACTION BETWEEN THE APJ RECEPTOR AND THE HIV VIRUS
    Publication number: 20020062488
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Application
    Filed: September 8, 1998
    Publication date: May 23, 2002
    Inventors: ROBERT W. DOMS, DARYL FAULDS, JOSEPH E. HESSELGESSER, RICHARD HORUK, BRANISLAVA MITROVIC, YIQING ZHOU
  • Novel interferon for the treatment of multiple sclerosis
    Publication number: 20020025304
    Abstract: This invention relates to novel nucleic acids and polypeptide sequences, which code for an interferon-beta-2 (“IFN-&bgr;2”). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-&bgr;2 polypeptide, biologically-active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans.
    Type: Application
    Filed: November 13, 2001
    Publication date: February 28, 2002
    Inventors: Edward M. Croze, Daryl Faulds, T. Charis Wagner
  • Pharmaceutical preparations for TNF inhibition
    Patent number: 6117895
    Abstract: Compounds of formula I ##STR1## are useful for treating TNF-mediated diseases.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: September 12, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Helmut Wachtel, Hermann Graf, Herbert Schneider, Daryl Faulds, H. Daniel Perez, Harald Dinter
  • Chiral methylphenyloxazolidinones
    Patent number: 6025376
    Abstract: This invention relates to (R)-(-)-methylphenyloxazolidinone derivatives, a process for their production and their use as pharmaceutical agents.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: February 15, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Henry Laurent, Eckhard Ottow, Gerald Kirsch, Helmut Wachtel, Herbert Schneider, Daryl Faulds, Harald Dinter